Skip to main content

Advertisement

SpringerLink
Log in

Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring

  • Letter to the Editor
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

A Short Communication to this article was published on 01 December 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168 (PubMed PMID: 29320654)

    Article  PubMed  CAS  Google Scholar 

  2. Imagawa A, Hanafusa T, Awata T et al (2012) Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J Diabetes Investig 3(6):536–539 (PubMed PMID: 24843620)

    Article  PubMed  PubMed Central  Google Scholar 

  3. Clotman K, Janssens K, Specenier P, Weets I, De Block CEM (2018) Programmed cell death-1 (PD-1) inhibitor induced type 1 diabetes mellitus: mini-review. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2018-00728. (PubMed PMID: 29955867)

    Article  PubMed  Google Scholar 

  4. Marchand L, Thivolet A, Dalle S et al. (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol https://doi.org/10.1007/s00592-018-1234-8 (PubMed PMID: 30284618)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes & Metabolism, Santa Croce e Carle Hospital, Cuneo, Italy

    Francesco Tassone, Elena Gamarra, Laura Gianotti, Claudia Baffoni, Giampaolo Magro & Giorgio Borretta

  2. Division of Oncology, Santa Croce e Carle Hospital, Cuneo, Italy

    Ida Colantonio

Authors
  1. Francesco Tassone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ida Colantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Gamarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura Gianotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claudia Baffoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giampaolo Magro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giorgio Borretta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Tassone.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Human and animal rights disclosure

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient.

Additional information

Managed by Massimo Porta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tassone, F., Colantonio, I., Gamarra, E. et al. Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta Diabetol 56, 489–490 (2019). https://doi.org/10.1007/s00592-018-1246-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-018-1246-4

Search

Navigation